Atrial Fibrillation
LILAC-TIMI 76: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Abelacimab in High-Risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
Cardiovascular Disease
AZURE-CVOT: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
OCEAN (a) PreEvent: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Heart Failure
BRANCH-HF: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948, in Adults With Heart Failure
HERMES: A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
EASi-HF Preserved: A Phase III Double-Blind, Randomized, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II–IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%
EASi-PROTKT™: A Phase III Double-Blind, Randomized, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension, and Established Cardiovascular Disease
EASi-HF Reduced: A Phase III Double-Blind, Randomized, Parallel-Group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II–IV) and Left Ventricular Ejection Fraction (LVEF) <40%
MARITIME-HF: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
PREVENT-HF: A Phase III, Randomized, Placebo-Controlled, Event-Driven Study to Evaluate the Effect of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death
Hypertension
Novartis HTN: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 12-Month Treatment Duration, Dose-Finding Study to Evaluate Efficacy, Safety, and Pharmacodynamics of QCZ484 in Mild to Moderate Hypertensive Patients
ZENITH: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
